Trevi Therapeutics Files 8-K Report
Ticker: TRVI · Form: 8-K · Filed: Oct 21, 2024 · CIK: 1563880
Sentiment: neutral
Topics: sec-filing, 8-k
Related Tickers: TRVI
TL;DR
Trevi Therapeutics (TRVI) filed an 8-K, likely routine. Keep an eye out for details.
AI Summary
On October 21, 2024, Trevi Therapeutics, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial transactions or material events are detailed in the provided excerpt, suggesting a routine or administrative filing.
Why It Matters
This filing signals that Trevi Therapeutics has made a disclosure to the SEC, which could contain important updates for investors, though the specific nature of the 'Other Events' is not detailed in this excerpt.
Risk Assessment
Risk Level: low — The filing is an 8-K reporting 'Other Events' without immediate details of significant financial or operational changes, suggesting a low immediate risk.
Key Players & Entities
- Trevi Therapeutics, Inc. (company) — Registrant
- 0000950170-24-115800 (filing_id) — Accession Number
- 20241021 (date) — Filing Date
- 195 Church Street, 16th Floor, New Haven, Connecticut 06510 (address) — Principal Executive Offices
- 203-304-2499 (phone_number) — Business Phone
FAQ
What specific 'Other Events' are being reported by Trevi Therapeutics in this 8-K filing?
The provided excerpt of the 8-K filing does not detail the specific 'Other Events' being reported by Trevi Therapeutics, Inc.
When was this 8-K report filed with the SEC?
This 8-K report was filed on October 21, 2024.
What is the exact name of the company filing this report?
The exact name of the registrant is Trevi Therapeutics, Inc.
What is the principal executive office address for Trevi Therapeutics?
The principal executive offices are located at 195 Church Street, 16th Floor, New Haven, Connecticut 06510.
What is the Commission File Number for Trevi Therapeutics?
The Commission File Number for Trevi Therapeutics is 001-38886.
Filing Stats: 625 words · 3 min read · ~2 pages · Grade level 14 · Accepted 2024-10-21 10:43:15
Key Financial Figures
- $0.001 — e on which registered Common stock, $0.001 par value per share TRVI The Nasdaq
Filing Documents
- trvi-20241021.htm (8-K) — 43KB
- 0000950170-24-115800.txt ( ) — 161KB
- trvi-20241021.xsd (EX-101.SCH) — 28KB
- trvi-20241021_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events On October 21, 2024, Trevi Therapeutics, Inc. (the "Company") announced that enrollment has been completed in the Company's Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) for the treatment of refractory chronic cough and the Company expects to report topline data in the first quarter of 2025.
Forward-Looking Statements
Forward-Looking Statements
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TREVI THERAPEUTICS, INC. Date: October 21, 2024 By: /s/ Lisa Delfini Name: Lisa Delfini Title: Chief Financial Officer